Trial Profile
Study AMB107818, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open Label Study of GSK1325760A to Evaluate the Safety and Efficacy of GSK1325760A - a Long-term Extension Study -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 Sep 2014 New trial record